The “Skinny” on Assessment and Utilization of Steatotic Liver Grafts: A Systematic Review

Kristopher P. Croome, David D. Lee, C. Burcin Taner – 28 February 2019 – The frequency at which steatotic deceased donor liver grafts are encountered will likely continue to increase. Utilization of liver grafts with moderate‐to‐severe steatosis for liver transplantation (LT) has been previously shown to be associated with increased rates of primary nonfunction and decreased recipient survival. In order to better inform clinical decision making and guide future research, critical evaluation of the literature on donor liver steatosis and posttransplantation outcome is needed.

Reply

Jaclyn LoPiccolo, Michael I. Brener, Kiyoko Oshima, Evan J. Lipson, James P. Hamilton – 28 February 2019

Manipulation of Lipid Metabolism During Normothermic Machine Perfusion: Effect of Defatting Therapies on Donor Liver Functional Recovery

Yuri L. Boteon, Joseph Attard, Amanda P. C. S. Boteon, Lorraine Wallace, Gary Reynolds, Stefan Hubscher, Darius F. Mirza, Hynek Mergental, Ricky H. Bhogal, Simon C. Afford – 28 February 2019 – Strategies to increase the use of steatotic donor livers are required to tackle the mortality on the transplant waiting list. We aimed to test the efficacy of pharmacological enhancement of the lipid metabolism of human livers during ex situ normothermic machine perfusion to promote defatting and improve the functional recovery of the organs.

Sorafenib in Hepatopulmonary Syndrome: A Randomized, Double‐Blind, Placebo‐Controlled Trial

Steven M. Kawut, Susan S. Ellenberg, Michael J. Krowka, David Goldberg, Hugo Vargas, David Koch, Tiffany Sharkoski, Nadine Al‐Naamani, Alyson Fox, Robert Brown, Joshua Levitsky, Jae K. Oh, Grace Lin, Nianfu Song, Carl Mottram, Margaret F. Doyle, David E. Kaplan, Samir Gupta, Michael B. Fallon – 28 February 2019 – The tyrosine kinase inhibitor sorafenib improves hepatopulmonary syndrome (HPS) in an experimental model. However, the efficacy and adverse effect profile in patients with HPS are unknown.

Neutrophil Gelatinase‐Associated Lipocalin for Assessment of Acute Kidney Injury in Cirrhosis: A Prospective Study

Patricia Huelin, Elsa Solà, Chiara Elia, Cristina Solé, Alessandro Risso, Rebeca Moreira, Marta Carol, Núria Fabrellas, Octavi Bassegoda, Adrià Juanola, Gloria de Prada, Sonia Albertos, Salvatore Piano, Isabel Graupera, Xavier Ariza, Laura Napoleone, Elisa Pose, Xavier Filella, Manuel Morales‐Ruiz, José Rios, Javier Fernández, Wladimiro Jiménez, Esteban Poch, Ferran Torres, Pere Ginès – 27 February 2019 – Kidney biomarkers appear to be useful in differential diagnosis between acute tubular necrosis (ATN) and other types of acute kidney injury (AKI) in cirrhosis, particularly hepatorenal syn

Subscribe to